The Problem With Gravity
To design a new drug, scientists often need to understand the precise, three-dimensional structure of a protein associated with a disease. They do this through a process called protein crystallization. On Earth, this is a notoriously difficult task. Gravity
causes convection and sedimentation, which can interfere with the formation of large, perfectly ordered crystals. Imagine trying to build a delicate tower of cards while the table is constantly being shaken; the same forces are at play on a molecular level. This often results in small or flawed crystals, which don't provide the high-resolution data needed to design effective drugs. This challenge contributes to the high costs and long timelines of pharmaceutical R&D, where it can take over a decade and billions of dollars to bring a new treatment to market.
The Microgravity Solution
In the near-weightlessness of low-Earth orbit, the physical constraints of gravity disappear. With convection and sedimentation removed, protein molecules can assemble into larger, more uniform, and more perfect crystals than is possible on the ground. In fact, studies have shown that in the majority of cases, crystals grown in space achieve significantly better resolution. This superior quality allows researchers to map the atomic structure of proteins, including their active sites where drugs bind, with unprecedented accuracy. This isn't just about better crystals; it leads to better science. Companies like Merck have already used the International Space Station (ISS) to improve the formulation of their blockbuster cancer drug, Keytruda. The applications also extend to creating more accurate 3D cell cultures that better mimic human tissues, which can accelerate disease modelling for conditions like cancer.
A New Commercial Frontier
For decades, this research was the exclusive domain of government agencies like NASA on the ISS. That is rapidly changing. With the ISS set to be decommissioned around 2030, a new ecosystem of private companies is racing to build its successors. Companies like Vast, Axiom Space, and the Starlab venture from Voyager Space and Airbus are all developing commercial space stations. Some, like Vast's Haven-1, plan to be free-flying outposts, while Axiom Space is initially attaching its modules to the ISS before detaching to become an independent station. This transition marks a pivotal shift from a single government-run lab to a competitive marketplace of orbital platforms, with NASA transitioning from owner to customer.
The Business of In-Orbit Labs
These new stations are being designed from the ground up as commercial research and manufacturing hubs. The business model involves leasing space and resources to pharmaceutical companies, research institutions, and even other countries. Some companies, like Varda Space Industries, are focused on a more specialised model: launching unmanned orbital capsules that manufacture drug formulations in space and then return the finished products to Earth. The goal is to move from pure research to actual in-space manufacturing. This emerging economy is attracting significant investment and creating a new supply chain where space companies act as highly specialised contract manufacturers for the pharmaceutical industry.
What It Means for India
This orbital revolution holds significant promise for India's powerful pharmaceutical sector, a global leader often called the 'pharmacy of the world'. As the Indian industry aims to move beyond generics and into novel drug discovery, microgravity research offers a pathway to accelerate innovation. Recognizing this, the Indian Space Research Organisation (ISRO) is already collaborating with the Department of Biotechnology and has shortlisted experiments for an upcoming collaborative mission to the ISS. This signals a clear intent to harness space-based research for national health priorities. For Indian pharma companies, access to commercial space platforms could provide a crucial competitive edge, enabling them to tackle complex diseases and develop next-generation therapies.
